-42%

est. 2Y upside i

HealthcareSeries B

MyOme is a clinical whole genome analysis platform company helping families understand their risk for inherited diseases.

Rank

#654

Sector

Biotechnology

Est. Liquidity

~4Y

Data Quality

Data: Medium

MyOme presents a strong upside opportunity, driven by its proprietary AI-integrated genomic analysis platform and a significant strategic partnership with Illumina, which includes investment and collaboration on a large-scale clinical trial.

Last updated: March 10, 2026

Bull (30%)+300%

MyOme's Proactive Health (MPH) trial, starting enrollment in 2026, successfully demonstrates significant patient outcomes and the projected $200B annual healthcare savings, leading to rapid adoption by healthcare systems. Strategic partnerships with Illumina and others expand market reach, pushing revenue to $100M+ by 2028 and justifying a $744M+ valuation at a premium multiple, well above the current $186M.

Base (45%)+75%

MyOme continues to grow steadily, leveraging its strong competitive moat with proprietary AI-integrated risk models and expanding its commercial products through existing partnerships. Revenue reaches $30M-$40M by 2028, leading to an acquisition or next funding round at a valuation of approximately $325M, representing a moderate return for common shareholders after accounting for liquidation preferences.

Bear (25%)-75%

Despite strong technology, MyOme faces slower-than-expected adoption due to long sales cycles in healthcare, intense competition from well-funded incumbents, or regulatory hurdles. The high capital intensity and current high valuation multiple (23.25x revenue) become unsustainable, leading to a down round or an exit below $100M. Given the $100M in liquidation preferences, common stock value is significantly diminished or wiped out.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

54%

Investors hold $100M in liquidation preferences. In an exit at or below $100M, common shareholders would receive nothing. If the company exits at the current $186M valuation, $100M would go to preferred shareholders, leaving $86M for common.

Dilution Risk

high

Given ongoing clinical trials and relatively early revenue, MyOme will likely require at least one more significant funding round (Series C/D) before an IPO or acquisition, leading to further dilution for existing shareholders.

Secondary Liquidity

active

Accredited investors can buy and sell MyOme stock on platforms like EquityZen and Premier Alternatives, offering some liquidity for early shareholders.

Other — 6 roles

View all 6 open roles at MyOme →

Last updated: February 22, 2026

Questions to Ask at the Interview

Strategic questions based on MyOme's data — designed to show you've done your homework.

  • 1

    “The MPH trial is projected to save $200 billion annually. How is MyOme planning to translate these projected savings into a sustainable and scalable revenue model, especially given the long sales cycles often associated with healthcare providers?”

  • 2

    “Given the strategic investment and collaboration with Illumina, how does MyOme envision its long-term relationship with Illumina evolving, and what measures are in place to maintain MyOme's independent competitive edge and intellectual property?”

  • 3

    “With $100M in total funding and a current valuation of $186M, what is the company's strategy for managing the preference stack to ensure meaningful returns for common shareholders in future liquidity events, and what is the anticipated timeline for such an event?”

Community

Valuation Sentiment

Our model estimates -42% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.